On May 28, 2022, Dr. Tom Du, Chairman of Evergreen Therapeutics and Dr. Charles Lee, CMO of Evergreen Therapeutics, attended the "First Academic Forum of HwaGen medical thinks markets 2022" sponsored by HwaGen Pharma. The conference was strongly supported by the local government, industry associations, and research institutions.
Dr. Tom Du delivers his speech during the “First Academic Forum” sponsored by HwaGen Pharma.
Dr. Charles Lee delivers his speech during the “First Academic Forum” sponsored by HwaGen Pharma.
At the meeting, a number of senior experts from pharmaceutical industry witnessed the launch ceremony of the one-stop CRO/CDMO platform of HwaGen Pharma, and discussed the future of small molecule innovative drugs. A roundtable discussion was held on the important role of small-molecule new drugs in the fight against COVID-19 and how to better attract financing for innovative drug companies under the current situation.
Dr. Tom Du and other experts witness the launch of the one-stop service platforms of HwaGen Pharma.
As leaders in innovative pharmaceuticals and as CRO enterprises in the domestic AI pharmaceutical field, Evergreen Therapeutics and HwaGen Pharma complement each other's strengths. With their high level of cooperation, they will jointly be building a new highland of innovative drugs in China. At the meeting, HwaGen Pharma officially appointed Dr. Tao Du as the company's Strategic Consultant and signed a strategic cooperation agreement with Evergreen Therapeutics.
Dr. Tom Du appointed as Strategic Consultant to HwaGen Pharma
Evergreen Therapeutics and HwaGen Pharma sign strategic cooperation agreement
About Evergreen Therapeutics
Evergreen Therapeutics is an international innovative pharmaceutical enterprise with "end-to-end" AI as its core technology. Founded in 2019, the company has offices and laboratories in Shenzhen, China, and Maryland, USA. Evergreen has a cross-disciplinary integrated team of top talents in clinical medicine, computational science, chemistry, pharmacology/toxicology, and FDA registration and regulation.
With the mission of "focusing on clinical needs and realizing medical value", Evergreen Therapeutics uses artificial intelligence technology (AI) to abandon homogenization hotspots, and has always insisted on the development strategy of globalization and differentiation, focusing on the research and development of innovative drugs in the fields of autoimmunity, tumor immunity, chronic diseases, ophthalmic drugs, and other fields. Evergreen explores new targets as well, reslizing companies are also actively developing new indications for existing drugs.
At present, Evergreen has 10 product pipelines, half of which have advanced to phase II and III clinical trials, and has more than 90 patent applications and 15 patents authorized, covering major global pharmaceutical markets such as China, the United States, Europe, and Japan.
Evergreen adheres to an open mind while vigorously promoting independent research and development. It is also actively promoting strategic cooperation, looking for cooperation opportunities around the world, introducing high-quality products and first-class technology, so as to meet the urgent clinical needs of patients as soon as possible and realize corporate value.
